Article Figures & Data
Figures
- Figure 1.
Median BVAS/WG with rituximab treatment. Box plot shows upper and lower quartiles; whiskers show maximum values. *P < 0.05 compared with time 0.
- Figure 2.
Mean ANCA titers (log-transformed) with rituximab treatment. Error bars show SEM. *P < 0.05 compared with time 0.
- Figure 3.
Median medication doses with rituximab treatment. Box plot shows upper and lower quartiles; whiskers show maximum and minimum values. *P < 0.05 compared with time 0.
Tables
Characteristics Complete Remission at Rituximab Initiation Partial Remission at Rituximab Initiation Combined Number 17 22 39 Number with anti-PR3/anti-MPO 11/6 13/9 24/15 Median age (range) 63 (25 to 87) 59.5 (39 to 88) 60 (25 to 88) Women (percent) 6 (35%) 14 (64%) 20 (51%) Median BVAS/WG at AAV diagnosis (range) 5 (1 to 8) 4.5 (1 to 9) 5 (1 to 9) Median BVAS/WG at rituximab initiation (range) 0 (NA) 2 (1 to 4) 1 (1 to 4) Median duration before rituximab, months (range) 51 (3 to 282) 71.5 (3 to 506) 67 (3 to 506) Number of relapses at rituximab initiation 0 8 5 13 1 to 2 7 11 18 >2 2 6 8 12 months of follow-up available 11 8 19 24 months of follow-up available 6 14 20 NA, not applicable.
Indications Complete Remission at Rituximab Initiation (n = 17) Partial Remission at Rituximab Initiation (n = 22) Combined Persistent symptoms attributable to AAV 0 8 8 Cyclophosphamide dependence (with or without symptoms) 4 4 8 Bone marrow toxicity 2 3 5 Steroid toxicity (e.g., weight gain, diabetes, avascular necrosis, osteoporotic fracture) 6 5 11 Rising or persistently high ANCA 4 10 14 Othera 2 2 4 ↵a Other includes severe fatigue (n = 2), patient desire to wean oral immunosuppression (n = 1), and bacterial pneumonia on cyclophosphamide and prednisone (n = 1).
In this issue
Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Jump to section
More in this TOC Section
Original Articles
Cited By...
- The Search for a Biomarker of Relapse in ANCA-Associated Vasculitis
- Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions
- Long-Term Maintenance Therapy Using Rituximab-Induced Continuous B-Cell Depletion in Patients with ANCA Vasculitis
- Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis?
- Documentation of off-label use of biologics in Rheumatoid Arthritis
- Decreased CD5+ B Cells in Active ANCA Vasculitis and Relapse after Rituximab
- Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
- Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry
- Rituximab Maintenance Therapy for Granulomatosis with Polyangiitis and Microscopic Polyangiitis
- B Cell Strategy to Maintain Remission in ANCA-associated Vasculitides?
- Rituximab Treatment for Vasculitis